Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | BRAF | P15056 | 8/20 | 0.45 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5586125 | 0.91 | KDR (0.42) | MAPK14MAPK13BRAFKDREPHB4 | |
| Cyclopropane SCHEMBL9107860 | 0.90 | BRAF (0.43) | BRAFKDREPHB4TEKRIPK1 | |
| SCHEMBL5959715 | 0.90 | KDR (0.44) | BRAFKDREPHB4TEKRIPK1 | |
| SCHEMBL9885318 | 0.90 | KDR (0.55) | MAPK14BRAFKDR | |
| SCHEMBL5959843 | 0.89 | KDR (0.43) | BRAFKDREPHB4TEKRIPK1 | |
| SCHEMBL5592775 | 0.87 | RIPK1 (0.49) | BRAFKDREPHB4TEKRIPK1 | |
| SCHEMBL5612386 | 0.87 | KDR (0.45) | BRAFKDREPHB4TEKRIPK1 | |
| SCHEMBL5586037 | 0.87 | RIPK1 (0.46) | BRAFKDREPHB4TEKRIPK1 | |
| SCHEMBL5612143 | 0.86 | EPHB4 (0.52) | BRAFKDREPHB4TEKRIPK1 | |
| SCHEMBL5592593 | 0.86 | KDR (0.46) | BRAFKDREPHB4TEKRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | claimed |
| EP-1858879-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | claimed |
| WO-2006076593-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2397478-A1 | 1,3-diaryl substituted ureas as modulators of kinase activity. | CGI Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-1858879-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006076593-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | UCK2, CHUK, AXL | MAPK14 262/4885MAPK13 110/4885BRAF 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.